Research & development
We pursue innovation that is patient-centred, scientifically rigorous, and socially responsible. Every project is designed to increase access, reduce cost burdens, and improve outcomes for patients around the world.
Ibogaine for PTSD
Our team has successfully formulated a low-dose ibogaine treatment for Post-Traumatic Stress Disorder (PTSD), which is now preparing to enter clinical trials.
High-Cost, Low-Volume Therapies
We currently have more than five projects in active development within orphan therapeutics, biosimilars, and specialty generics.
iSMART® Technology
iSMART technology revolutionises patient care with its innovative approach, reducing healthcare burdens, empowering clinicians, and improving patient access to timely and effective treatments.
Nicotine Replacement Therapy
We have obtained approvals from the MHRA, EMA, and other authorities for our Nicotine Replacement Therapy (NRT) product, launched as NOS®.